Vizora日本語

ADR Biomedical HoldingsADR Biomedical Holdings Inc.3750東証スタンダード情報・通信業FY ending Mar 2026, consolidated, J-GAAP

ADR Biomedical Holdings FY ending Mar 2024 results

About 92% of ADR Biomedical Holdings's sales come from Real Asset, with Medical making up much of the rest.

It lost about ¥49 for every ¥100 of sales at the operating level.

Revenue changed -27.2% from the prior year.

What changed from last year

FY ending Mar 2023 → FY ending Mar 2024

Revenue
-27.2%¥2.14B → ¥1.56B
Gross profit
+1.9%¥1.27B → ¥1.29B
Operating income
Loss-¥794.4M → -¥772.7M
Net income attributable to owners
Back to profit-¥1.06B → ¥138.2M
Operating cash flow
Loss-¥39.5M → -¥1.15B
Free cash flow
Loss-¥198M → -¥1.17B

Where the money goes

FY ending Mar 2023 → FY ending Mar 2024

Where ¥100 of sales goes

For every ¥100 ADR Biomedical Holdings sells, how much goes where, and how much is kept.

FY ending Mar 2024
Cost of sales
¥17
SG&A
¥132
Operating loss
¥49
Net profit kept
¥9

Annual margin trends

Gross margin82.8%
FY ending Mar 2020: 64.1%64.1%FY ending Mar 2021: 54.8%54.8%FY ending Mar 2022: 64.3%64.3%FY ending Mar 2023: 59.2%59.2%FY ending Mar 2024: 82.8%82.8%FY20FY21FY22FY23FY24
Operating margin-49.5%
FY ending Mar 2020: -10.9%-10.9%FY ending Mar 2021: -52.7%-52.7%FY ending Mar 2022: -34.6%-34.6%FY ending Mar 2023: -37.0%-37.0%FY ending Mar 2024: -49.5%-49.5%FY20FY21FY22FY23FY24
Net margin8.9%
FY ending Mar 2020: 27.1%27.1%FY ending Mar 2021: -59.9%-59.9%FY ending Mar 2022: -5.8%-5.8%FY ending Mar 2023: -49.4%-49.4%FY ending Mar 2024: 8.9%8.9%FY20FY21FY22FY23FY24

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2024
  • Real Asset¥1.43B
    92%
    Op. margin -2.2%
  • Medical¥126.4M
    8%
    Op. margin -439.9%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第22期(2025/04/01－2026/03/31)

    ID S100YLDW2026-06-26Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第21期(2024/04/01－2025/03/31)

    ID S100WZTN2025-11-07Open

  • EDINET (FSA Japan)

    有価証券報告書－第20期(2023/04/01－2024/03/31)

    ID S100TUF62024-06-26Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第19期(2022/04/01－2023/03/31)

    ID S100RS4G2023-08-30Open

  • EDINET (FSA Japan)

    有価証券報告書－第18期(令和3年4月1日－令和4年3月31日)

    ID S100OEC72022-06-23Open

  • EDINET (FSA Japan)

    有価証券報告書－第17期(令和2年4月1日－令和3年3月31日)

    ID S100LPPV2021-06-24Open

Extracted from XBRL: 48 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image